Becker's Healthcare March 11, 2024
Wegovy is now approved to be used to reduce the risk of heart attack, stroke and cardiovascular death, which could lead to broader payer coverage of the drug.
On March 8, The FDA approved Novo Nordisk’s weight loss drug to be used for preventing cardiovascular events in adults with cardiovascular disease who are also obese or overweight.
The approval is a “paradigm shift in obesity treatment and payer coverage,” BMO Capital Markets analyst Evan Seigerman wrote in a research note reported by The Wall Street Journal March 8.
GLP-1 drugs, which include Ozempic, Trulicity, Victoza and Mounjaro, are approved to treat Type 2 diabetes, though these drugs are prescribed off-label for weight loss. Wegovy and Saxenda are...
Today's Sponsors
Today's Sponsor